0
0
HYDERABAD — For patients battling ocular tuberculosis (TB), finishing a grueling six-to-nine-month course of antibiotics is usually the finish line. However, a groundbreaking international study reveals that for nearly one in five patients, the “cure” does not immediately mean the end of the threat to their vision.
Researchers have discovered that a specific, vision-threatening form of the disease known as Tubercular Serpiginous-Like Choroiditis (TB-SLC) can cause persistent eye inflammation even after the bacteria have been successfully eradicated. This lingering inflammation is not caused by a failure of the antibiotics, but by a “hyper-responsive” immune system that continues to attack the eye long after the infection is gone.
The study, published in Translational Vision Science & Technology on December 29, 2025, and gaining widespread clinical attention in April 2026, suggests a major shift in how doctors treat the disease: focusing less on the bacteria and more on aggressive immune suppression in the early stages of care.
The “Invasive Weed” Problem: Understanding TB-SLC
Ocular tuberculosis occurs when Mycobacterium tuberculosis—the same bacteria responsible for lung TB—travels through the bloodstream to the eye. In the case of TB-SLC, the bacteria settle in the choroid, the layer of blood vessels nourishing the retina.
The disease creates snake-like, “serpiginous” lesions that crawl across the back of the eye. If these lesions reach the macula (the center of vision), the damage is often permanent. Medical experts often compare the condition to a garden overrun by invasive weeds. While anti-tubercular therapy (ATT) acts like a weed killer to remove the plants, the “roots” of the immune response can continue to churn up the soil, causing damage long after the weeds are dead.
To diagnose this, doctors use Fundus Autofluorescence (FAF), a specialized imaging technique that allows them to see the “glow” of active inflammation. In a healthy eye, the borders of these lesions should quiet down after treatment; in persistent cases, they remain dangerously active.
Key Findings: The “Month 3” Milestone
The study, led by researchers at India’s LV Prasad Eye Institute (LVPEI) in collaboration with the Cleveland Cole Eye Institute, reviewed 94 eyes from 65 patients treated between 2016 and 2023.
The data revealed several critical insights for both doctors and patients:
-
The 18.5% Factor: Nearly one-fifth of patients showed active inflammation at the end of their antibiotic course, despite a microbiological cure.
-
The “Window of Opportunity”: Patients who received lower doses of anti-inflammatory medications (steroids or immunosuppressants) during the first month of treatment were significantly more likely to face persistent issues.
-
Early Warning Signs: If inflammation was still visible at the three-month check-up, the risk of it persisting past the end of treatment skyrocketed (Adjusted Odds Ratio: 13.44).
“When an infectious disease persists after prolonged antimicrobial therapy, it is a challenge for the doctor,” explains Dr. Soumyava Basu, lead author and Head of Uveitis Services at LVPEI. “Our study demonstrates that factors beyond infection could also be driving late persistence of inflammation.”
Expert Perspectives: A Shift in Strategy
The findings have sparked a dialogue among global uveitis specialists. The central takeaway is that TB-SLC behaves less like a standard infection and more like an autoimmune disorder triggered by an infection.
Dr. Vishali Gupta, a renowned uveitis specialist at the Post Graduate Institute of Medical Education and Research (not involved in the study), has previously noted that while antibiotics are essential to prevent recurrence, they are only half the battle.
Collaborator Dr. Natasha Kesav of the Cole Eye Institute highlighted the importance of the Total Immunosuppressive Load (TIL)—a scored measurement of the intensity of anti-inflammatory treatment. The study found that a higher TIL in the first 30 days acts as a protective shield, preventing the immune system from entering a state of chronic overactivity.
Public Health and the “Post-TB” Reality
In India, which sees approximately 2.6 million TB cases annually, ocular TB is a significant cause of preventable blindness. This study highlights a growing recognition of “Post-TB Disease”—a phenomenon also seen in the lungs and joints where the body’s immune “memory” causes chronic damage even after the bacteria are gone.
Implications for Patients
For those currently undergoing treatment, the study offers a roadmap for safeguarding their sight:
-
Demand Early Intensity: Discuss the “TIL” or the intensity of your steroid regimen with your doctor. Being “aggressive” with anti-inflammatories in month one may save your vision in month nine.
-
Monitor via Imaging: Ensure your clinic uses FAF imaging at the three-month mark. This is the most reliable way to catch “silent” inflammation that you might not yet feel as a symptom.
-
Don’t Panic if Inflammation Stays: The study found that 88% of persistent cases were eventually resolved by simply increasing anti-inflammatory drugs, without needing to restart or change the antibiotics.
Limitations and Future Outlook
While the study is a breakthrough, researchers noted some limitations. The study was retrospective, meaning it looked at past data rather than following new patients in real-time. Additionally, while the immune response was the likely culprit, rare cases of multi-drug resistant (MDR) TB could not be 100% ruled out without invasive biopsies, though the high success rate of steroid treatment makes MDR-TB an unlikely cause for most.
The Path Forward
The discovery of this “tight central cluster” of risk factors—low early steroids and lingering month-three inflammation—gives clinicians a clear target. By shifting the focus from “killing the bug” to “calming the storm,” thousands of patients in TB-endemic regions may be able to avoid the scarring and vision loss that once seemed inevitable.
As Dr. Basu notes, there is a “rolling window of opportunity.” If caught and treated with the right balance of antibiotics and immune-suppressing drugs, the “invasive weeds” of TB-SLC can be stopped before they claim a patient’s sight.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
https://health.economictimes.indiatimes.com/news/industry/eye-tb-inflammation-may-persist-even-after-cure-says-study/130058328?utm_source=top_story&utm_medium=homepage
